Koshinski Asset Management Inc. Takes $968,000 Position in Laboratory Corp. of America Holdings (LH)

Koshinski Asset Management Inc. purchased a new position in shares of Laboratory Corp. of America Holdings (NYSE:LH) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 6,071 shares of the medical research company’s stock, valued at approximately $968,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Janus Henderson Group PLC grew its holdings in Laboratory Corp. of America by 5,992.1% in the 2nd quarter. Janus Henderson Group PLC now owns 889,631 shares of the medical research company’s stock valued at $137,128,000 after buying an additional 875,028 shares in the last quarter. Empyrean Capital Partners LP acquired a new position in shares of Laboratory Corp. of America in the 2nd quarter valued at $92,484,000. JPMorgan Chase & Co. lifted its stake in shares of Laboratory Corp. of America by 57.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,350,903 shares of the medical research company’s stock valued at $202,298,000 after purchasing an additional 492,866 shares during the last quarter. HealthCor Management L.P. lifted its stake in shares of Laboratory Corp. of America by 34.1% in the 2nd quarter. HealthCor Management L.P. now owns 1,375,000 shares of the medical research company’s stock valued at $211,943,000 after purchasing an additional 350,000 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Laboratory Corp. of America by 174.8% in the 2nd quarter. Renaissance Technologies LLC now owns 506,405 shares of the medical research company’s stock valued at $78,057,000 after purchasing an additional 322,100 shares during the last quarter. Hedge funds and other institutional investors own 90.87% of the company’s stock.

In other Laboratory Corp. of America news, Director Adam H. Schechter sold 1,263 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $169.29, for a total transaction of $213,813.27. Following the completion of the sale, the director now directly owns 7,297 shares of the company’s stock, valued at approximately $1,235,309.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.90% of the stock is currently owned by company insiders.

Laboratory Corp. of America Holdings (NYSE LH) traded up $2.62 during trading hours on Friday, reaching $168.08. The company had a trading volume of 936,233 shares, compared to its average volume of 663,657. The stock has a market cap of $17,271.39, a P/E ratio of 13.77, a PEG ratio of 1.49 and a beta of 0.93. The company has a quick ratio of 1.75, a current ratio of 1.31 and a debt-to-equity ratio of 0.93. Laboratory Corp. of America Holdings has a 12-month low of $133.65 and a 12-month high of $181.71.

Laboratory Corp. of America (NYSE:LH) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $2.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.07. The firm had revenue of $2.70 billion for the quarter, compared to the consensus estimate of $2.70 billion. Laboratory Corp. of America had a return on equity of 16.30% and a net margin of 12.15%. The firm’s quarterly revenue was up 13.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.15 EPS. equities research analysts predict that Laboratory Corp. of America Holdings will post 11.48 EPS for the current fiscal year.

Several equities analysts have recently commented on the company. Zacks Investment Research raised Laboratory Corp. of America from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. ValuEngine lowered Laboratory Corp. of America from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. Craig Hallum reissued a “buy” rating and set a $204.00 target price (up previously from $180.00) on shares of Laboratory Corp. of America in a research note on Wednesday. Citigroup increased their target price on Laboratory Corp. of America from $161.00 to $184.00 and gave the stock a “neutral” rating in a research note on Friday. Finally, Mizuho set a $165.00 price target on Laboratory Corp. of America and gave the stock a “neutral” rating in a report on Friday, December 1st. Six equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $180.73.

ILLEGAL ACTIVITY WARNING: This piece of content was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://ledgergazette.com/2018/02/10/koshinski-asset-management-inc-invests-968000-in-laboratory-corp-of-america-holdings-lh.html.

About Laboratory Corp. of America

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply